This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Ottawa directory, so their courses and email address may be missing. Find their university profile.
Latest papers
Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.
Molecular therapy : the journal of the American Society of Gene Therapy · 2010
Latest funding
- $50,000
COVID-19 Variant Supplement - Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals
CIHR · 2021 · Principal investigator
- $1,936,150
Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals
CIHR · 2020 · Principal investigator
1 publications.
Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.
Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H, Bell JC, McCart JA, Mahoney D, Stojdl DF
COVID-19 Variant Supplement - Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals
Principal investigators: Bell, John C; Ilkow, Carolina S; Lapointe, Réjean; Mahoney, Douglas J
Keywords: Covid-19; Epitopes; Immunity; Infection; Manufacturing; Pre-Clinical; Sars-Cov-2; Vaccine
Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals
Principal investigators: Bell, John C; Ilkow, Carolina S; Lapointe, Réjean; Mahoney, Douglas J
Keywords: Covid-19; Epitopes; Immunity; Infection; Manufacturing; Pre-Clinical; Sars-Cov-2; Vaccine
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.